drugset / Trial / NCT04535063
Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia
Phase 3
Completed
200 enrolled
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
NaSingle-groupOpen-labelTreatment
Summary
To determinate feasibility, safety and outcome with convalescent plasma in patients with severe COVID-19 penumonia
Timeline
- Start
- 2020-04-18
- Primary completion
- 2020-12-30
- Completion
- 2021-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COVID19 convalescent plasma infusion | Unknown | 300 ml | Intravenous |
| Subject | COVID19 convalescent plasma infusion | Unknown | 600 ml | Intravenous |